Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
QuintilesIMS
Johnson and Johnson
Mallinckrodt
UBS
Cantor Fitzgerald

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 7,625,875

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,625,875
Title:2\' and 3\'-nucleoside prodrugs for treating Flaviviridae infections
Abstract: 2\' and 3\'-Prodrugs of 1\', 2\', 3\' or 4\'-branched .beta.-D or .beta.-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
Inventor(s): Gosselin; Gilles (Monpellier, FR), Storer; Richard (Folkstone, GB), LaColla; Paola (Cagliari, IT), Sommadossi; Jean-Pierre (Cambridge, MA)
Assignee: Idenix Pharmaceuticals, Inc. (Cambridge, MA) Universita Degli Studi di Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR)
Application Number:11/005,444
Patent Claims:see list of patent claims

Details for Patent 7,625,875

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Vidara Therapeutics Research Ltd ACTIMMUNE interferon gamma-1b VIAL; SINGLE-USE 103836 001 1999-02-25 ➤ Sign Up Idenix Pharmaceuticals, Inc. (Cambridge, MA) Universita Degli Studi di Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07 ➤ Sign Up Idenix Pharmaceuticals, Inc. (Cambridge, MA) Universita Degli Studi di Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07 ➤ Sign Up Idenix Pharmaceuticals, Inc. (Cambridge, MA) Universita Degli Studi di Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Sign Up Idenix Pharmaceuticals, Inc. (Cambridge, MA) Universita Degli Studi di Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 7,625,875

Country Patent Number Publication Date
South Africa 200410249 Oct 29, 2008
South Africa 200410290 Sep 26, 2007
South Africa 200504954 Jan 28, 2009
World Intellectual Property Organization (WIPO) 2004002422 Apr 07, 2005
World Intellectual Property Organization (WIPO) 2004002422 Jan 08, 2004
World Intellectual Property Organization (WIPO) 2004002999 Aug 12, 2004
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Mallinckrodt
Moodys
Johnson and Johnson
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.